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CASE REPORT
INDICATIONS OF CARBAPENEM RESISTANCE EVOLUTION THROUGH HETERORESISTANCE AS AN 
INTERMEDIATE STAGE IN Acinetobacter baumannii AFTER CARBAPENEM ADMINISTRATION
Silvana Vargas SUPERTI(1), Daniela de Souza MARTINS(1), Juliana CAIERÃO(1), Fabiana da Silva SOARES(1), Taísa PROCHNOW(1) & Alexandre Prehn ZAVASCKI(2)
SUMMARY
We describe an in vivo evolution of an antimicrobial profile from susceptibility to full-resistance to carbapenems, with 
heteroresistance as an intermediate stage, in an Acinetobacter baumannii strain. Heteroresistance was characterized by the growth 
of sub-populations within the susceptibility halo in both disk-diffusion and Etest. PCRs for the main A. baumannii carbapenemases 
were negative. The exact resistance mechanism, diagnostic methods and clinical relevance of heteroresistance in A. baumannii 
warrant further investigations. This is the first description of such phenomenon in vivo and the second report of heteroresistance to 
carbapenems in A. baumannii.
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INTRODUCTION
Acinetobacter baumannii, which is associated with a wide range 
of infections, particularly pneumonia among intensive care unit (ICU) 
patients, has emerged as an important nosocomial pathogen in many 
parts of the world4. The carbapenems, imipenem and meropenem, are 
among the drugs of choice used to treat nosocomial infections due to 
multidrug-resistant A. baumannii isolates4.
As other Gram-negative rods, resistance in these bacteria is known 
to be homogeneous within a culture although a report has described the 
spread of hetero-carbapenem-resistant A. baumannii isolates7. In the 
present report, we describe the recovery from blood of an A. baumannii 
isolate presenting heteroresistance to carbapenems in a patient receiving 
meropenem due to an intra-abdominal abscess.
CASE REPORT
In March 2006, a first A. baumannii resistant to both imipenem 
and meropenem was identified in our institution12. Two isolates were 
recovered from an intra-abdominal abscess secretion and from the blood 
of a 67-year-old female patient at ICU, respectively. Identification of the 
isolates has been based on biochemical tests, including mobility, oxidase 
activity, oxidation of glucose on OF-medium; and API 20 NE method 
(6.0 version, bio-Merieux, Marcy L’Etoile, France). This patient was 
receiving I.V. meropenem (1g IV every eight hours) for exactly 31 days, 
for the treatment of the abscess after an esophagectomy for a carcinoma 
of the esophagus. The therapy was changed for polymyxin B (75 mg IV 
every 12 hours) when the culture results became available (three days 
after collection), but the patient ultimately died of septic shock seven 
days after starting new antimicrobial treatment. 
The phenotypic profile of this isolate showed heteroresistance to both 
imipenem and meropenem, as indicated by the growth of sub-populations 
within the clear zone of inhibition, which demonstrated susceptibility (20 
and 19 mm, respectively) in the disk-diffusion test (Fig. 1A), performed 
according to Clinical Laboratory Standards Institute guidelines3. The 
test was repeated with the sub-populations and the same phenotypic 
profile was observed, i.e. the growth of resistant sub-populations within 
the zone of inhibition with a diameter indicating susceptibility. These 
findings were confirmed using the Etest (AB Biodisk, Solna, Sweden) 
(Fig. 1B). The same phenotypic phenomenon was observed when the 
sub-populations were re-tested. 
Phenotypic tests for MBL detection using a disk approximation test 
with imipenem (Oxoid) in the presence of EDTA were negative for both 
isolates. Additionally, PCR for carbapenemases genes (blaIMP, blaVIM, 
blaSPM, bla OXA-23, bla OXA-24, bla OXA-51 and blaOXA-58 was carried out using 
specific primers as described elsewhere1-5, but there was no product of 
amplification for any primers, except for the blaOXA-51. 
Forty-three days latter, a carbapenem-resistant A. baumannii was 
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recovered from a tracheal aspirate of a 44-years male ICU patient, who 
was under mechanical ventilation due to severe tetanus. This patient 
received I.V. meropenem (1g t.i.d.) during the previous 12 days as 
empirical treatment for a ventilator-associated pneumonia. This isolate 
was fully resistant to imipenem and meropenem (MIC >32 µg/mL for 
both) by Etest method.
Both hetero and full-resistant isolates were submitted to molecular 
typing with other A. baumannii isolate previously recovered from patients 
at ICU and proved to be the same strain of a carbapenem-susceptible 
isolate recovered 102 days before the recovery of the heteroresistant one. 
This latter patient was a 65-year-old woman with erythematous systemic 
lupus, who was hospitalized at ICU and presented the A. baumannii 
recovered from the tracheal aspirate and blood. This patient had not 
received carbapenem.
DISCUSSION
We presented a rare case of a carbapenem-heteroresistant A. baumannii 
recovered from blood and abscess secretion of a patient receiving 
meropenem therapy. A previous report has described heteroresistance 
to carbapenems in eight A. baumannii isolates which were also neither 
MBL nor oxacillinase producers7. As in this previous study, the exact 
mechanism of resistance in our strain could not be determined. Although 
the main A. baumannii carbapenemases have been ruled out, the isolate 
carried a gene encoding an OXA-51-like group β-lactamase, a gene 
present in most A. baumannii strains, but with a non-clearly defined role 
in carbapenem resistance11.
Heteroresistance, which may be defined as a phenotypic manifestation 
of resistance within a genetically homogeneous strain10, has only rarely 
been described in Gram-negative bacteria6-9. Although authors are not 
certain about the clinical impact of this resistance phenotype in Gram-
negative rods, our report suggests that heteroresistance may adversely 
affect the outcome of patients, since the A. baumannii isolate was 
recovered from the blood of a patient receiving meropenem therapy. 
In conclusion, heteroresistance in nonfermentative Gram-negative 
bacteria is a rare and poorly understood phenomenon, the exact 
mechanism determining this phenotype, the best diagnostic methods and 
its clinical relevance warrant further investigations. 
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RESUMO
Indicações da evolução da resistência ao carbapenem através da 
heteroresistência como estágio intermediário no Acinetobacter 
baumannii após administração de carbapenem
Descrevemos a evolução in vivo, de um perfil de sensibilidade 
aos antimicrobianos, passando de sensibilidade a resistência total 
aos antibióticos carbapenêmicos, com um estágio intermediário 
de heteroresistência em isolado de Acinetobacter baumannii. A 
heteroresistência foi caracterizada pelo crescimento de sub-população 
na zona de inibição pelo método de disco-difusão e pelo Etest. PCRs 
para as principais carbapenemases envolvidas com resistência neste 
microrganismo foram negativas. O exato mecanismo de resistência 
envolvido, método diagnóstico e relevância clínica justificam investigação 
adicional. Esta é a primeira descrição deste fenômeno in vivo e o segundo 
relato de heteroresistência em A. baumannii.
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Fig. 1 - Disk-diffusion (A) for imipenem and Etest (B) for meropenem showing the growth 
of resistant sub-populations of Acinetobacter baumannii. 
Fig. 2 - Pulsed-field gel electrophoresis showing a high degree of similarity between the 
heteroresitant isolate (A), fully resistant isolate (B) and  carbapenem-susceptible isolates 
previously recovered in our institution (C).
SUPERTI, S.V.; MARTINS, D.S.; CAIERÃO, J.; SOARES, F.S.; PROCHNOW, T. & ZAVASCKI, A.P. - Indications of carbapenem resistance evolution through heteroresistance as an 
intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev. Inst. Med. trop. S. Paulo, 51(2): 111-113, 2009.
113
 2. BOU, G.; OLIVER, A. & MARTINEZ-BELTRAN, J. - OXA-24, a novel class D beta-
lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. 
Antimicrob. Agents Chemother., 44: 1556-1561, 2000.
 3. CLINICAL AND LABORATORY STANDARDS INSTITUTE - M100-S16, Performance 
Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement. 
Wayne, CLSI, 2006.
 4. DIJKSHOORN, L.; NEMEC, A. & SEIFERT, H. - An increasing threat in hospitals: 
multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol., 5: 939-951, 
2007.
 5. ELLINGTON, M.J.; KISTLER, J.; LIVERMORE, D.M. & WOODFORD, N. - Multiplex 
PCR for rapid detection of genes encoding acquired metallo-ß-lactamases. J. 
Antimicrob. Chemother., 59: 321-322, 2007.
 6. LI, J.; RAYNER, C.R.; NATION, R.L. et al. - Heteroresistance to colistin in multidrug-
resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., 50: 2946-2950, 
2006.
 7. POURNARAS, S.; IKONOMIDIS, A.; MARKOGIANNAKIS, A.; MANIATIS, A.N. 
& TSAKRIS, A. - Heteroresistance to carbapenems in Acinetobacter baumannii. J. 
Antimicrob. Chemother., 55: 1055-1056, 2005.
 8. POURNARAS, S.; IKONOMIDIS, A.; MARKOGIANNAKIS, A. et al. - Characterization 
of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to 
carbapenems. J. med. Microbiol., 56: 66-70, 2007.
 9. POURNARAS, S.; IKONOMIDIS, A.; NEOU, E. et al. - Piperacillin/tazobactam-
heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated 
by piperacillin/tazobactam. J. Antimicrob. Chemother., 61: 757-758, 2008. 
 10. RINDER, H. - Hetero-resistance: an under-recognized confounder in diagnosis and 
therapy? J. med. Microbiol., 50: 1018-1020, 2001.
 11. TURTON, J.F.; WOODFORD, N.; GLOVER, J. et al. - Identification of Acinetobacter 
baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this 
species. J. clin. Microbiol., 44: 2974-2976, 2006.
 12. ZAVASCKI, A.P.; SOARES, F.C.; SUPERTI, S.V. et al. - Stable carbapenem susceptibility 
rates among multidrug-resistant Acinetobacter spp. strains in a setting of high 
prevalence of carbapenem-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. 
Agents, 30: 187-189, 2007.
Received: 9 September 2008
Accepted: 5 March 2009
